Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Q32 Bio (QTTB) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Q32 Bio (QTTB) over the last 5 years, with Q3 2025 value amounting to $12.2 million.

  • Q32 Bio's Shares Outstanding (Diluted Average) rose 135.91% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 135.91%. This contributed to the annual value of $9.7 million for FY2024, which is 266677.25% up from last year.
  • Latest data reveals that Q32 Bio reported Shares Outstanding (Diluted Average) of $12.2 million as of Q3 2025, which was up 135.91% from $12.2 million recorded in Q2 2025.
  • In the past 5 years, Q32 Bio's Shares Outstanding (Diluted Average) ranged from a high of $57.9 million in Q3 2022 and a low of $344623.0 during Q1 2023
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $12.2 million (2025), whereas its average is $27.6 million.
  • In the last 5 years, Q32 Bio's Shares Outstanding (Diluted Average) tumbled by 9940.45% in 2023 and then soared by 337730.79% in 2024.
  • Quarter analysis of 5 years shows Q32 Bio's Shares Outstanding (Diluted Average) stood at $55.3 million in 2021, then rose by 3.83% to $57.4 million in 2022, then tumbled by 99.39% to $349060.0 in 2023, then surged by 2666.77% to $9.7 million in 2024, then rose by 26.74% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $12.2 million for Q2 2025, and $12.2 million during Q1 2025.